Esophageal Cancer Clinical Trial

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Summary

The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS).

View Full Description

Full Description

Pembrolizumab (200 mg) or placebo will be administered intravenously [IV] on day 1 of each 3-week cycle. Trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance dose) will be administered IV on day 1 of each 3-week cycle. SOC chemotherapy for the global cohort will either be FP (80 mg/m^2 cisplatin administered IV on Day 1 of each 3-week cycle and 800 mg/m^2 5-fluorouracil [5-FU] administered IV on Days 1-5 of each 3-week cycle) or CAPOX (1000 mg/m^2 capecitabine administered orally twice daily [BID] on days 1-14 of each 3-week cycle and 130 mg/m^2 oxaliplatin administered IV on Day 1 of each 3-week cycle). A Japan cohort will receive SOX chemotherapy consisting of S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine [CDHP], and potassium oxonate [Oxo]) administered orally BID according to Body Surface Area (BSA) on Days 1-14 of each 3-week cycle and oxaliplatin (130 mg/m^2) administered IV on Day 1 each 3-week cycle.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically or cytologically confirmed diagnosis of previously untreated, locally advanced unresectable or metastatic HER2 positive gastric or GEJ adenocarcinoma
HER2-positive defined as either immunohistochemistry (IHC) 3+ or IHC 2+ in combination with in-situ hybridization positive (ISH+) or fluorescent in-situ hybridization (FISH), as assessed by central review on primary or metastatic tumor
Has measurable disease as defined by RECIST 1.1 as determined by the site investigator
Male participants must agree to use approved contraception
Female participants who are not pregnant or breastfeeding, and who are either not a woman of childbearing potential (WOCBP), or are a WOCBP who agrees to use approved contraception
Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale within 3 days prior to the first dose of trial treatment
Has a life expectancy of greater than 6 months
Has adequate organ function

Exclusion Criteria:

Has had previous therapy for locally advanced unresectable or metastatic gastric/GEJ cancer
Has had major surgery, open biopsy or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment
Has had radiotherapy within 14 days of randomization
Has a known additional malignancy that is progressing or has required active treatment within the past 5 years
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Has an active autoimmune disease that has required systemic treatment in past 2 years
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
Has a known history of active tuberculosis (TB; Mycobacterium tuberculosis)
Has an active infection requiring systemic therapy
Has poorly controlled diarrhea
Accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment. If the participant is receiving diuretic drugs for other reasons, it is acceptable
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
Has peripheral neuropathy > Grade 1
Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial
A WOCBP who has a positive urine pregnancy test within 24 hours prior to randomization or treatment allocation
Has active or clinically significant cardiac disease
Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection
Has severe hypersensitivity (≥Grade 3) to pembrolizumab, trastuzumab, study chemotherapy agents and/or to any excipients, murine proteins, or platinum-containing products
Has had an allogeneic tissue/solid organ transplant
Has received prior therapy with an anti-PD-1, anti-immunotherapy-drugs-are-boosting-survival/" >PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX 40, Cluster of Differentiation 137 [CD137])

Study is for people with:

Esophageal Cancer

Phase:

Phase 3

Estimated Enrollment:

738

Study ID:

NCT03615326

Recruitment Status:

Active, not recruiting

Sponsor:

Merck Sharp & Dohme LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 187 Locations for this study

See Locations Near You

UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0045)
Los Angeles California, 90095, United States
Pacific Cancer Care ( Site 0063)
Monterey California, 93940, United States
UC Irvine Medical Center/Chao Family Comprehensive Cancer Center ( Site 0050)
Orange California, 92868, United States
University of Miami Sylvester Comprehensive Cancer Center - Plantation ( Site 0026)
Miami Florida, 33136, United States
Southeastern Regional Medical Center, Inc. ( Site 0058)
Newnan Georgia, 30265, United States
Midwestern Regional Medical Center, Inc. ( Site 0059)
Zion Illinois, 60099, United States
Beth Israel Deaconess Medical Center ( Site 0070)
Boston Massachusetts, 02215, United States
Dana-Farber Cancer Institute [Boston, MA] ( Site 0010)
Boston Massachusetts, 02215, United States
Minnesota Oncology Hematology, PA ( Site 8001)
Minneapolis Minnesota, 55404, United States
Washington University School of Medicine ( Site 0040)
Saint Louis Missouri, 63110, United States
Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0071)
Middletown New Jersey, 07748, United States
Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 0065)
Harrison New York, 10604, United States
Memorial Sloan-Kettering Cancer Center ( Site 0017)
New York New York, 10065, United States
University of Rochester ( Site 0041)
Rochester New York, 14642, United States
Levine Cancer Institute ( Site 0015)
Charlotte North Carolina, 28204, United States
Duke Cancer Institute ( Site 0042)
Durham North Carolina, 27710, United States
CTCA Southwestern ( Site 0060)
Tulsa Oklahoma, 74133, United States
Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0025)
Philadelphia Pennsylvania, 19124, United States
Allegheny General Hospital ( Site 0053)
Pittsburgh Pennsylvania, 15212, United States
Sanford Hematology Oncology-Sioux Falls SD ( Site 0004)
Sioux Falls South Dakota, 57104, United States
University of Texas MD Anderson Cancer Center ( Site 0001)
Houston Texas, 77030, United States
Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 8000)
Roanoke Virginia, 24014, United States
Seattle Cancer Care Alliance ( Site 0038)
Seattle Washington, 98109, United States
Liverpool Hospital ( Site 2206)
Liverpool New South Wales, 2170, Australia
Westmead Hospital ( Site 2200)
Westmead New South Wales, 2145, Australia
Southern Medical Day Care Centre ( Site 2207)
Wollongong New South Wales, 2500, Australia
Monash Health ( Site 2202)
Clayton Victoria, 3168, Australia
Hospital Sao Rafael ( Site 0209)
Salvador Bahia, 41253, Brazil
Instituto do Cancer do Ceara ( Site 0208)
Fortaleza Ceara, 60430, Brazil
CIONC - Centro Integrado de Oncologia de Curitiba ( Site 0205)
Curitiba Parana, 80810, Brazil
Hospital de Caridade de Ijui ( Site 0202)
Ijui Rio Grande Do Sul, 98700, Brazil
Hospital Nossa Senhora da Conceicao ( Site 0203)
Porto Alegre Rio Grande Do Sul, 91350, Brazil
CEPON - Centro de Pesquisas Oncologicas ( Site 0200)
Florianopolis Santa Catarina, 88034, Brazil
Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0201)
Rio de Janeiro , 20231, Brazil
IBCC - Instituto Brasileiro de Controle do Cancer ( Site 0204)
Sao Paulo , 03102, Brazil
Centro Investigación del Cáncer James Lind ( Site 0300)
Temuco Araucania, 47800, Chile
Clinica Universidad Catolica del Maule ( Site 0305)
Talca Maule, 34600, Chile
Fundacion Arturo Lopez Perez FALP ( Site 0302)
Santiago Region M. De Santiago, 75009, Chile
Pontificia Universidad Catolica de Chile ( Site 0301)
Santiago Region M. De Santiago, 76200, Chile
Instituto Nacional del Cancer ( Site 0303)
Santiago Region M. De Santiago, 83804, Chile
Shanghai General Hospital ( Site 2404)
Shanghai Anhui, 20008, China
Peking Union Medical College Hospital ( Site 2419)
Beijing Beijing, 10003, China
Fifth Medical Center of CPLA General Hospital ( Site 2415)
Beijing Beijing, 10007, China
Beijing Cancer Hospital ( Site 2413)
Beijing Beijing, 10014, China
Fujian Provincial Cancer Hospital ( Site 2418)
Fuzhou Fujian, 35001, China
900 Hospital of the Joint ( Site 2420)
Fuzhou Fujian, 35002, China
The First Affiliated Hospital of Xiamen University ( Site 2431)
Xiamen Fujian, 36100, China
Guangdong General Hospital ( Site 2433)
Guangzhou Guangdong, 51008, China
Harbin Medical University Cancer Hospital ( Site 2407)
Harbin Heilongjiang, 15008, China
Henan Cancer Hospital ( Site 2400)
Zhengzhou Henan, 45000, China
Xiangya Hospital Central-South University ( Site 2426)
Changsha Hunan, 41000, China
Jiangsu Cancer Hospital ( Site 2432)
Nanjing Jiangsu, 21000, China
The First Hospital Of Jilin University ( Site 2402)
Chang chun Jilin, 13002, China
Fudan University Shanghai Cancer Center ( Site 2424)
Shanghai Shanghai, 20003, China
Zhongshan Hospital affiliated to Fudan University ( Site 2401)
Shanghai Shanghai, 20003, China
Cancer Hospital Affiliated to Xinjiang Medical University ( Site 2430)
Urumqi Xinjiang, 83000, China
The First Affiliated Hospital.Zhejiang University ( Site 2408)
Hangzhou Zhejiang, 31000, China
Sir Run Run Shaw Hospital ( Site 2412)
Hangzhou Zhejiang, 31001, China
Zhejiang Cancer Hospital ( Site 2409)
Hangzhou Zhejiang, 31002, China
CHU de Rouen ( Site 0912)
Rouen Ain, 76000, France
HUS Hopital Hautepierre ( Site 0910)
Strasbourg Bas-Rhin, 67098, France
Hopital Jean Minjoz Besancon ( Site 0901)
Besancon Doubs, 25030, France
C.H.R.U. de Brest - Hopital Morvan ( Site 0913)
Brest Finistere, 29200, France
Centre Oscar Lambret ( Site 0911)
Lille Nord, 59000, France
Centre Leon Berard ( Site 0904)
Lyon Rhone, 69008, France
Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0902)
Saint-Herblain Val-de-Marne, 44805, France
Institut Gustave Roussy ( Site 0900)
Villejuif Val-de-Marne, 94805, France
CHU Hopital Saint Antoine ( Site 0905)
Paris , 75012, France
SLK-Kliniken Heilbronn ( Site 1015)
Heilbronn Baden-Wurttemberg, 74078, Germany
Klinikum Ludwigsburg ( Site 1014)
Ludwigsburg Baden-Wurttemberg, , Germany
Innere Medizin I, Universitaetsklinikum Tuebingen ( Site 1020)
Tuebingen Baden-Wurttemberg, 72076, Germany
Klinikum rechts der Isar der Technischen Universitaet ( Site 1027)
Muenchen Bayern, 81675, Germany
Medizinische Hochschule Hannover ( Site 1019)
Hannover Niedersachsen, 30625, Germany
Universitaetsklinikum Carl Gustav Carus der Technischen Univ ( Site 1001)
Dresden Sachsen, 01307, Germany
Universitaetsklinikum Leipzig AOeR ( Site 1007)
Leipzig Sachsen, 04103, Germany
Charite-Universitaetsmedizin Berlin Campus Virchow-Klinikum ( Site 1026)
Berlin , 13353, Germany
Klinikum Bremen Nord ( Site 1017)
Bremen , 28211, Germany
Facharztzentrum Eppendorf ( Site 1025)
Hamburg , 20249, Germany
Asklepios Klinik Altona ( Site 1000)
Hamburg , 22763, Germany
Celan SA ( Site 0504)
Guatemala , 01010, Guatemala
Oncomedica ( Site 0500)
Guatemala , 01010, Guatemala
Grupo Angeles SA ( Site 0501)
Guatemala , 01015, Guatemala
Nucare Center ( Site 0506)
Guatemala , 01015, Guatemala
Medi-K Cayala ( Site 0505)
Guatemala , 01016, Guatemala
Centro Regional de Sub Especialidades Medicas SA ( Site 0502)
Quetzaltenango , 09001, Guatemala
Saint James's Hospital ( Site 1505)
Dublin , D08NH, Ireland
Beaumont Hospital ( Site 1506)
Dublin , D09 V, Ireland
Tallaght University Hospital ( Site 1513)
Dublin , D24 N, Ireland
Soroka University Medical Center ( Site 1603)
Beer Sheva , 84101, Israel
Rambam Health Care Campus ( Site 1606)
Haifa , 31096, Israel
Edith Wolfson Medical Center ( Site 1605)
Holon , 58220, Israel
Hadassah Ein Kerem Medical Center ( Site 1604)
Jerusalem , 91120, Israel
Meir Medical Center ( Site 1609)
Kfar-Saba , 44281, Israel
Rabin Medical Center ( Site 1602)
Petah Tikva , 49414, Israel
Chaim Sheba Medical Center. ( Site 1607)
Ramat Gan , 52656, Israel
Sourasky Medical Center ( Site 1601)
Tel Aviv , 64239, Israel
AUOP Ospedale Santa Chiara ( Site 1100)
Pisa Toscana, 56126, Italy
Humanitas Gavazzeni ( Site 1106)
Bergamo , 24125, Italy
Universita Magna Graecia di Catanzaro ( Site 1107)
Catanzaro , 88100, Italy
IEO Istituto Europeo di Oncologia ( Site 1105)
Milano , 20141, Italy
Azienda Ospedaliero - Universitaria Policlinico di Modena ( Site 1102)
Modena , 41124, Italy
A.O.U. Universita degli Studi della Campania-Luigi Vanvitelli ( Site 1103)
Napoli , 80131, Italy
Istituto Oncologico Veneto ( Site 1101)
Padova , 35128, Italy
Ospedale Civile Spirito Santo ( Site 1104)
Pescara , 65100, Italy
Aichi Cancer Center Hospital ( Site 2617)
Nagoya Aichi, 464-8, Japan
National Cancer Center Hospital East ( Site 2605)
Kashiwa Chiba, 277-8, Japan
National Hospital Organization Shikoku Cancer Center ( Site 2615)
Matsuyama Ehime, 791-0, Japan
Gunma Prefectural Cancer Center ( Site 2602)
Ohta Gunma, 373-8, Japan
Hyogo Cancer Center ( Site 2619)
Akashi Hyogo, 673-8, Japan
Kobe City Medical Center General Hospital ( Site 2614)
Kobe Hyogo, 650-0, Japan
Ibaraki Prefectural Central Hospital ( Site 2611)
Kasama Ibaraki, 309-1, Japan
Kagawa University Hospital ( Site 2604)
Kita-gun Kagawa, 761-0, Japan
Kanagawa Cancer Center ( Site 2603)
Yokohama Kanagawa, 241-8, Japan
Osaki Citizen Hospital ( Site 2626)
Osaki Miyagi, 989-6, Japan
Kansai Medical University Hospital ( Site 2618)
Hirakata Osaka, 573-1, Japan
Kindai University Hospital ( Site 2616)
Osakasayama Osaka, 589-8, Japan
Osaka University Hospital ( Site 2600)
Suita Osaka, 565-0, Japan
Saitama Cancer Center ( Site 2620)
Kitaadachi-gun Saitama, 362-0, Japan
Shizuoka Cancer Center Hospital and Research Institute ( Site 2607)
Sunto-gun Shizuoka, 411-8, Japan
Tochigi Cancer Center ( Site 2627)
Utsunomiya Tochigi, 320-0, Japan
Kyorin University Hospital ( Site 2608)
Mitaka Tokyo, 181-8, Japan
Chiba Cancer Center ( Site 2623)
Chiba , 260-8, Japan
National Hospital Organization Kyushu Cancer Center ( Site 2609)
Fukuoka , 811-1, Japan
Gifu University Hospital ( Site 2621)
Gifu , 501-1, Japan
Hiroshima City Hiroshima Citizens Hospital ( Site 2625)
Hiroshima , 730-8, Japan
Kumamoto University Hospital ( Site 2601)
Kumamoto , 860-8, Japan
Niigata Cancer Center Hospital ( Site 2622)
Niigata , 951-8, Japan
National Hospital Organization - Osaka National Hospital - Institute For Clinical Research ( Site 26
Osaka , 540-0, Japan
Osaka International Cancer Institute ( Site 2613)
Osaka , 541-8, Japan
Osaka General Medical Center ( Site 2624)
Osaka , 558-8, Japan
National Cancer Center Hospital ( Site 2612)
Tokyo , 104-0, Japan
Toranomon Hospital ( Site 2628)
Tokyo , 105-8, Japan
Tokyo Metropolitan Komagome Hospital ( Site 2606)
Tokyo , 113-8, Japan
The Cancer Institute Hospital of JFCR ( Site 2610)
Tokyo , 135-8, Japan
Seoul National University Hospital ( Site 2703)
Seoul , 03080, Korea, Republic of
Severance Hospital Yonsei University Health System ( Site 2700)
Seoul , 03722, Korea, Republic of
Asan Medical Center ( Site 2702)
Seoul , 05505, Korea, Republic of
Samsung Medical Center ( Site 2701)
Seoul , 06351, Korea, Republic of
Auckland City Hospital ( Site 2300)
Auckland , 1023, New Zealand
Uniwersytecki Szpital Kliniczny im. J. M. Radeckiego we Wroclawiu ( Site 1705)
Wroclaw Dolnoslaskie, 50-55, Poland
Dolnoslaskie Centrum Onkologii. ( Site 1712)
Wroclaw Dolnoslaskie, 53-41, Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie ( Site 1709)
Lublin Lubelskie, 20-08, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
Warszawa Mazowieckie, 02-78, Poland
Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1715)
Gdynia Pomorskie, 81-51, Poland
Szpital Specjalistyczny w Koscierzynie Sp. z o.o. ( Site 1708)
Koscierzyna Pomorskie, 83-40, Poland
Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1710)
Bielsko-Biala Slaskie, 43-30, Poland
Przychodnia Lekarska Komed ( Site 1716)
Konin Wielkopolskie, 62-50, Poland
Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1807)
Ufa Baskortostan, Respublika, 45005, Russian Federation
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1815)
Chelyabinsk Chelyabinskaya Oblast, 45408, Russian Federation
Podolsky City Clinical Hospital ( Site 1817)
Podolsk Moskovskaya Oblast, 14211, Russian Federation
Blokhin National Medical Oncology ( Site 1805)
Moscow Moskva, 11547, Russian Federation
Medical University REAVIZ ( Site 1816)
Samara Samarskaya Oblast, 44301, Russian Federation
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1801)
Saint Petersburg Sankt-Peterburg, 19775, Russian Federation
St Petersburg City Clinical Oncology Dispensary ( Site 1812)
Saint Petersburg Sankt-Peterburg, 19825, Russian Federation
Leningrad Regional Oncology Center ( Site 1800)
Saint-Petersburg Sankt-Peterburg, 18866, Russian Federation
Hospital General Universitario de Elche ( Site 1404)
Elche Alicante, 03203, Spain
Hospital Universitario Central de Asturias ( Site 1402)
Oviedo Asturias, 33011, Spain
Hospital Germans Trias i Pujol. ICO de Badalona ( Site 1410)
Badalona Barcelona, 08916, Spain
Hospital Universitario Marques de Valdecilla ( Site 1405)
Santander Cantabria, 39008, Spain
Hospital Universitario Quiron Madrid ( Site 1407)
Pozuelo de Alarcon Madrid, 28223, Spain
Hospital General Universitari Vall d Hebron ( Site 1401)
Barcelona , 08035, Spain
Hospital Universitario Ramon y Cajal ( Site 1400)
Madrid , 28034, Spain
Adana Sehir Hastanesi ( Site 2002)
Adana , 01370, Turkey
Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 2017)
Ankara , 06100, Turkey
Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi ( Site 2006)
Ankara , 06200, Turkey
Trakya Universitesi Tip Fakultesi ( Site 2015)
Edirne , 22030, Turkey
Ataturk Universitesi Tip Fakultesi Hastanesi ( Site 2000)
Erzurum , 25240, Turkey
Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 2001)
Istanbul , 34098, Turkey
Dokuz Eylul Universitesi Tip Fakultesi Hastanesi ( Site 2011)
Izmir , 35340, Turkey
Malatya Inonu Universitesi Tip Fakultesi Hastanesi ( Site 2009)
Malatya , 44280, Turkey
Sakarya Universitesi Egitim ve Arastirma Hastanesi ( Site 2012)
Sakarya , 54290, Turkey
City Clinical Hosp.4 of DCC ( Site 2102)
Dnipro Dnipropetrovska Oblast, 49102, Ukraine
MI Kryviy Rih Center of Dnipropetrovsk Regional Council ( Site 2101)
Kryviy Rih Dnipropetrovska Oblast, 50048, Ukraine
MI Precarpathian Clinical Oncology Center ( Site 2105)
Ivano-Frankivsk Ivano-Frankivska Oblast, 76018, Ukraine
Communal non profit enterprise Regional Clinical Oncology Center ( Site 2112)
Kharkiv Kharkivska Oblast, 61070, Ukraine
Medical Center Asklepion LLC ( Site 2115)
Khodosivka Kyivska Oblast, 08173, Ukraine
Clinic of National Cancer Institute ( Site 2104)
Kyiv Kyivska Oblast, 03022, Ukraine
Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 2114)
Kyiv Kyivska Oblast, 03126, Ukraine
Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 2106)
Lviv Lvivska Oblast, 79031, Ukraine
MI Odessa Regional Oncological Centre ( Site 2108)
Odesa Odeska Oblast, 65055, Ukraine
Medical Centre LLC Oncolife ( Site 2103)
Zaporizhzhya Zaporizka Oblast, 69104, Ukraine
Kyiv City Clinical Oncology Centre ( Site 2110)
Kyiv , 03115, Ukraine
Royal Hospital in Derby ( Site 1514)
Derby Derbyshire, DE22 , United Kingdom
Ninewells Hospital and Medical School ( Site 1504)
Dundee Dundee City, DD1 9, United Kingdom
Castle Hill Hospital ( Site 1501)
Cottingham East Riding Of Yorkshire, HU16 , United Kingdom
University College London Hospital NHS Foundation Trust ( Site 1508)
London London, City Of, NW1 2, United Kingdom
St Georges University Hospitals NHS Foundation Trust. ( Site 1500)
London London, City Of, SW17 , United Kingdom
Royal Marsden Hospital ( Site 1510)
Sutton Surrey, SM2 5, United Kingdom
Royal Marsden NHS Foundation Trust ( Site 1512)
London , SW3 6, United Kingdom
The Christie Hospital NHS Foundation Trust ( Site 1503)
Manchester , M20 4, United Kingdom
Mount Vernon Cancer Centre ( Site 1507)
Northwood , HA6 2, United Kingdom
Manor Hospital Walsall England ( Site 1515)
Walsall , WS2 9, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Esophageal Cancer

Phase:

Phase 3

Estimated Enrollment:

738

Study ID:

NCT03615326

Recruitment Status:

Active, not recruiting

Sponsor:


Merck Sharp & Dohme LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.